« Return to News | Drug Sponsors

Par to acquire Edict Pharmaceuticals

Tuesday, May 24, 2011 10:31 AM

New Jersey-based Par Pharmaceutical, which specializes in high barrier-to-entry generics and niche branded drugs, will acquire Indian generic drug maker Edict Pharmaceuticals in a deal worth up to $37.6 million in cash, according to Pharma Times.

Edict, which develops and manufactures solid oral dosage generics, has a "strong product pipeline focused on niche first-to-file, first-to-market formulations."  The company currently has seven ANDAs filed with the FDA (plus one ANDA submitted in the name of a development partner) with an additional 14 products in development.

Par's president Paul Campanelli noted that Edict's facility adds significant operational capacity and provides business continuity protection" for the firm's plant in New York. He added that the company "has a long-standing relationship" with Edict's chief executive, Muthusamy Shanmugan, "having collaborated on numerous current Par products."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.